ABSTRACT Starch gel electrophoresis and inhibition studies with L-phenylalanine, L-homoarginine, L-leucine, Lleucylglycylglycine, and L-phenylalanylglycylgylcine were carried out on a series of human-alkaline phosphatases [orthophosphoric-monoester phosphohydrolase (alkaline optimum); EC 3.1.3.1] derived from fetal and adult liver, kidney, bone, and intestine. No differences between adult and fetal liver, kidney, or bone alkaline phosphatases were observed by either electrophoretic or inhibition studies. However, the fetal intestinal enzyme could be clearly distinguished from the adult intestinal enzyme by its greater anodal electrophoretic mobility and its retardation after treatment with neuraminidase. Even after extensive neuraminidase treatment, its anodal mobility was still slightly greater than that of adult intestinal alkaline phosphatase. Fetal and adult intestinal enzymes showed the same inhibition profiles with the series of inhibitors both before and after treatment with neuraminidase.
by thermostability studies (15, 16) , and by immunological methods (3, (17) (18) (19) (20) .
The placental alkaline phosphatase phenotype is determined by the genotype of the fetus and not by that of the mother (5) . Thus, the placental enzyme can be regarded as a "fetal" enzyme. In the work reported here we compare fetal samples of other tissues with corresponding adult samples in order to see whether further forms of alkaline phosphatase characteristic of fetal life and perhaps attributable to other loci could be identified.
MATERIALS AND METHODS
Samples. Adult liver, kidney, bone, and intestinal samples were obtained from autopsies generally conducted within 12 hr of death. Fetal tissue samples were obtained post mortem from induced elective abortions or at autopsy from babies delivered prematurely who expired shortly after delivery. Meconium samples (first stool of the newborn) came from an unselected series of births at the Hospital of the University of Pennsylvania. The tissue samples were stored at -20°if not used immediately.
Extraction was carried out by a modification of the butanol method of Morton (21) . A small quantity of tissue was homogenized in the presence of an equal volume of water and half this volume of n-butanol with a Polytron homogenizer (Brinkman). The homogenate was incubated for 0.5 hr at 370 and then centrifuged (12,100 X g, 20 min, 50). The intermediate aqueous layer was removed and used for the analyses.
Crude intestinal extracts usually contained, in addition to the characteristic intestinal alkaline phosphatase, a liver-like alkaline phosphatase. Prior to inhibition studies on these extracts, they were heated at 560 for about 90 min. This treatment results in the complete destruction of the liver-like enzyme while only 40-50% of the intestinal enzyme activity is lost. Electrophoresis after neuraminidase treatment established that the liver-like component was completely destroyed; in addition, further heating caused no additional change in the inhibition characteristics of the sample.
Electrophoresis. Starch gel electrophoresis of the tissue extracts was carried out at 50 using a Tris borate discontinuous buffer system, pH 8.0-8.6 (6) . Neuraminidase treatment was performed by mixing a volume of sample (0.5 ml) with an equal volume of 10.0 mM Na2EIPO4/citrate buffer, pH 5.0, containing one unit of neuraminidase (Sigma type VI), and incubating for 60 min at 370.
Enzyme Assays and Inhibition Studies. Alkaline phosphatase activity was determined at 300 in a 1.0-ml reaction mixture containing 5.0 mnM p-nitrophenyl phosphate (Sigma), 1 Table 2 summarizes the inhibition results on ten different samples of adult intestinal alkaline phosphatase and eight samples of the fetal intestinal enzyme. The inhibition profiles for this battery of inhibitors are essentially the same for both the fetal and adult forms of the enzyme. There is marked inhibition with L-phenylalanine, modest inhibition with L-leucine, and only slight inhibition with L-homoarginine, L-leucylglycylglycine, and L-phenylalanylglycylglycine at the concentrations of inhibitors used. The inhibition profile is clearly distinct from that obtained from bone, liver, kidney, or placental alkaline phosphatases (11) .
Inhibition results on 20 samples of meconium alkaline phosphatase are also given in Table 2 . Other studies have shown that meconium, the first stool of the newborn, is rich in the enzyme, and we have found that this is very similar to the fetal intestinal enzyme in its electrophoretic properties both before and after neuraminidase treatment. As shown in Table 2 , the meconium enzyme has essentially the same inhibition profile as the fetal and adult intestinal enzymes.
In order to learn whether removal of the sialic acid residues affected the inhibition characteristics of the fetal intestinal or meconium alkaline phosphatase, we examined a sample of each before and after neuraminidase treatment and compared them to a sample of the adult intestinal enzyme treated in a similar manner. Each sample (0.1 ml) was mixed with 0.5 ml of 5.0mM Na2HPO4/citrate buffer, pH 5.0 containing one unit of neuraminidase and incubated for 1 hr at 370. At the same time, a control sample (0.1 ml) was mixed with 0.5 ml of the same buffer as the treated sample, only lacking the neuraminidase, and was also incubated for 1 hr at 37°. After incubation, the samples were dialyzed against 10 mM Tris-HCI, pH 7.5/1.0 mM MgCI2. The results of the inhibition studies both with and without neuraminidase treatment are shown in Table 3 Table 4 summarizes the inhibition results with the liver, bone, and kidney enzymes from the three fetuses and with a number of adult samples of alkaline phosphatase from these organs. The inhibition profiles were essentially the same for both the fetal and adult samples and for each of the tissues. Marked inhibition was obtained with L-homoarginine, modest inhibition with L-leucine and L-leucylglycylglycine, and only slight inhibition with L-phenylalanine and L-phenylalanylglycylglycine at the concentrations of the inhibitor used. It has been shown previously that treatment with neuraminidase does not affect the inhibition profile or activity of liver, bone, and kidney alkaline phosphatases (11).
DISCUSSION
Alkaline phosphatases from different fetal tissues were compared with those from corresponding adult tissues to see whether significant molecular differences occur. The methods used would have allowed us to distinguish enzyme molecules that differed in their total net charge before and after removal of sialic acid residues or that differed in their binding sites for a series of uncompetitive small molecular weight inhibitors.
No electrophoretic differences between fetal and adult alkaline phosphatases from liver, bone, and kidney were oh. served. All three enzymes from both fetal and adult tissues also gave essentially the same inhibition profiles with the series of inhibitors used. Thus, there is no suggestion of a further locus coding for any of these enzymes being expressed in fetal life, at least after about 20 weeks gestation.
In contrast, six samples of intestinal alkaline phosphatase obtained before 25 weeks gestation could be clearly distinguished from the adult intestinal enzyme by electrophoresis. They had a greater anodal mobility than the adult enzyme and also, unlike the adult enzyme, their electrophoretic mobility was retarded after treatment with neuraminidase. Further examples of this fetal intestinal enzyme were found in fetuses of greater gestational age, and the overall results suggest that the changeover from synthesis of the fetal form to the adult form starts to occur between 28 and 32 weeks of gestation.
The fetal and adult forms of intestinal alkaline phosphatase clearly differ in their content of sialic acid residues. However, even after these have been removed, some molecular difference appears to remain. Whether this is due to a further difference in the carbohydrate moiety or to a difference in the protein, which might imply coding by a separate gene locus, cannot be answered by simple electrophoretic analysis. The finding that the fetal and adult intestinal enzymes showed the same inhibition profiles indicates that the binding sites for the series of different inhibitors used are likely to be the same in the two classes of molecules.
It has been reported that the alkaline phosphatase in meconium has a different electrophoretic mobility from the adult intestinal enzyme (22) , and Miki et al. (23) showed that it had a mobility similar to that of the intestinal enzyme from a stillborn fetus (6 months gestation). Furthermore, the electropho- Inhibition is expressed as the mean percentage of original activity remaining (+SD) in the presence of the inhibitor. Number of samples is given in parentheses.
retic mobility of meconium alkaline phosphatase was retarded by neuraminidase, though in a number of other properties it resembled the adult intestinal enzyme. We have confirmed this result in a series of 27 meconium samples and compared them with a series of fetal intestinal samples. It appears that the meconium enzyme is mostly fetal intestinal in type. It probably has its origin in desquamated fetal intestinal mucosa and progressively accumulates during the course of fetal life.
Thus, as late as 28-32 weeks of gestation an intestinal alkaline phosphatase different from that seen in the adult can be observed. The molecular basis of this difference is still uncertain, and it is not clear whether it represents the expression of different gene loci or whether it is due to some difference in post-translational modification. However, it is of interest that alklline phosphatase resembling the fetal intestinal enzyme has been demonstrated in at least two reports of hepatocellular carcinoma (24, 25) . Since a placental-like alkaline phosphatase has also been observed in various other malignant tumors (4, 26) , both fetal forms of the enzyme may be aberrantly expressed in malignancy.
